top of page

Challenges for Creation.


About CellionBioMed Inc.

In order to establish CellionBioMed, we have devoted 15 years of research to elucidate the role of potassium (K+) channel on the cell membrane. The role of K+ channel has not yet been revealed and left it as unknown. This field has been studied in recent decades to reveal the function and mechanism within the cell—a fundamental of a human body. Because the research is sophisticated and requires highly skilled techniques, successful research has been limited by the research groups in this field. 


Due to novel method of the research strategy, we have first discovered that K+ channels are in charge of key roles in intercellular activity, especially in significance of vascular endothelial celIs, fibrosis, and inflammation. With the novel discovery as a basis of our technology, CellionBioMed is able to develop several first-in-class drug candidates for treating incurable diseases such as liver cirrhosis, pulmonary hypertension, autoimmune diseases, and other untreatable diseases. In order to retain the intellectual property, we are also able to file patents on our discovery through research, accordingly. 
Additionally, our novel discovery of the role of K+ channels of the cell essentially applies to development of new diagnostic method for vascular diseases and screening for severity of cancers. This new diagnostic method will provide notable standard of healthy state of human blood vascular system.  
It is our ultimate goal that all members of Cellion BioMed to commit all of our efforts towards success of our technology to be in use for human health and to bring happier life to people.


Thank you, ​​​​​​​  ​​​​​​​  ​​​​​​​  ​​​​​​​

S. J. Kim, Ph.D ​​​​​​​

President & CEO

CellionBioMed Inc.



김 성진 사진(1).jpg

President & CEO  - ​​​​​​​Seong Jin Kim, Ph.D​​​​​​​

products, one of the most honorable awards in Korean scientific society. In addition to the award, he was also awarded a ‘Grand Prize’ from the Ministry of commerce, and a ‘Testimony’ from the Ministry of Health and Welfare on his contribution on healthcare to the society.


His experiences in diverse companies and careers in establishment and management of start-up biotech companies are certainly valuable asset for CellionBioMed on its successful foundation.

Dr. Kim has established CellionBioMed Inc. in 2018. He is in charge of business development and planning clinical priority strategies. He is also responsible for designing molecules and synthesis of them.


Dr. Kim has diverse experience in industries and start up bio-venture companies. After completing his Ph.D in bio-organic chemistry at Vanderbilt University,  Dr. Kim transitioned his bio-chemical study at Cornell University for his postdoc research. Dr. Kim found his industrial career at R&D Center in Samsung combined with his previous experience at R&D Center in LG Life Science. 


As a passionate scientist, he founded RStech Corporation, a company with core-technology in pharmaceutical ingredients. Through having a unique deep-rooted technology, RStech stands for more than 18 years in its professional field. Dr. Kim also contributed his passion to AnyGen. His management to AnyGen in its early stage consolidated the biotech company successfully and grew it as a listed company.


What is more to his entrepreneurial achievement is that Dr. Kim was awarded ‘Jang Young-Shil Award' from the Ministry of Science and Technology, which is given to the person who contributed in innovated technology on commercialization of high-tech

SSH_profile photo edit_2.png

CTO & Core Scientific Advisor  - ​​​​​​​Suk H. Suh, MD., Ph.D​​​​​​​

Dr. Suh is a pure medical scientist in physiology.  Dr. Suh has earned his MD degree in​​​​​​​ Medical School of Seoul National University. After earning his medical doctorate, his desire ​​​​​​​in natural ​​​​​​​science led him to devote himself in physiological science to learn principles of ​​​​​​​natural ​​​​​​​medical science in which he also earned Ph.D ​​​​​​​ in Medical School of Seoul National ​​​​​​​University.  ​​​​​​​


After earning his degree of M.D. and ​​​​​​​Ph.D,​​​​​​​ he has continued his research in physiology as a ​​​professor in Medical School of Ehwa ​​​​​​​Womans ​​​​​​​University.  ​​​​​​​


Dr. Suh has achieved successful research in physiology and resulted in valuable outcomes. ​​​​​​​Especially, Dr. Suh is one of the most leading ​​​​​​​scientists in ​​​​​​​ the field of ion channel study. ​​​​​​​In ​​​​​​​addition, every member of his research group was trained thoroughly so that incomparable ​​​​​​​results were able to be brought up and any competition has not been allowed from other ​​​​​​​research groups abroad. ​​​​​​​


Dr. Suh has ​​​​​​​first discovered the principles of K+ channels in cell biology that acts as key roles in life and health of cells. ​​​​​​​


Owing to Dr. Suh's frontier achievements on elucidating undiscovered scientific world, CellionBioMed is able to ​​​​​​​entreasure​​​​​​​ ​​​​​​​ valuable technologies, which will lead successful contribution to human society of well-being. ​​​​​​​


Managing Director  - ​​​​​​​Seon-Myung Kim, Ph.D​​​​​​​

Dr. Seon-Myung Kim obtained his undergraduate degree in Microbiology from the Pusan National University in South Korea. He earned his MS and Ph.D in Department of Life Science from GIST (Gwangju Institute of Science and Technology), where he studied the cell dynamics and imaging. 

Dr. Kim joined Emory University as a postdoc in 2010, where he worked on collaborative project studying the signal transduction and cytoskeletal mechanisms underlying neuronal development, disorder and regeneration under the guidance of Dr. James Zheng at Emory University School of Medicine. In 2014, Dr. Kim transitioned to his position as R&D team leader in AnyGen Co. Ltd. and held various roles in pre-clinical and clinical studies of anti-cancer and anti-diabetic drug candidates. Also, he was involved in IPO(Inital Public Offering) preparation stage. Finally AnyGen successfully enlisted on KOSDAQ in 2016. 

After his career in AnyGen, he co-founded WellPep Co., Ltd which is specialized in discovering and developing novel peptide therapeutics for the treatment of infections. He was responsible for managing research projects and grants and developing the business strategy. 

He joined CellionBionMed Inc. in 2021 as a R&D director. 

Our Discovery

Our Discovery

We have first discovered that regulation of K+ channels on the cell membrane plays key roles on the vital activity of the cells, intercellular signaling, causes of diverse diseases such as liver cirrhosis, autoimmune, blood vascular disorders by fibrosis and inflammations.


We also first discovered that up-regulation of Kca 2. 3 and Kca 3. 1 channel restrained 

blood vessel diseases and verified the mechanism. Also, we found that down-regulation of Kca 2.3 and Kca 3.1 channel caused dysfunction of vascular endothelial cells and diseases of blood vessel.


Through our discovery, we found several first-in-class drug candidates for liver cirrhosis, pulmonary hypertension, auto-immunes, and blood vessel diseases.


Our novel discovery of the role of K+ channels of the cell essentially applies for the development of new diagnostic system for vascular diseases and prognosing severity of cancers which were not able to be diagnosed by current methods.

Technology Portfolio

Roles of Ion Channels in Health and Diseases

221217_Roles of ion channels_icons_pills.png

New Drugs

- Anti-inflammation

- Anti-Fibrosis

- Liver Cirrhosis 

221217_Roles of ion channels_icons_health.png

Health Cares

- Cosmeceutical Skin Care

- Scar or keloid treatment


- Retard vascular aging

221217_Roles of ion channels_icons_chart.png

New Diagnosis

- Diagnosis of vascular diseases
- Healthy state of blood vessel

-Diagnosis of cancers
Prognosis & severity

Strategy of our development

Development of new drugs is highly risky as it is a financially and timely consuming process. Our strategy is to discover drug candidates among molecules which were already verified in safety and toxicity.  
By applying our unique drug screening system, we acquire new applications from which are currently prescribed for other diseases. By applying "drug re-positioning" method, we pursue our drug development with minimal risk and high success as well as rapid process.   


Our promising drug candidates are targeted to: ​​​​​​​  ​​​​​​​ 

• Liver cirrhosis (CBM-N1)
• Pulmonary hypertension (CBM-NX)
• Treatment of scar and keloid (CBM-C1) 
• Pulmonary fibrosis (CBM-NX) 
• Autoimmune disease (CBM-NX, CBM-FX) 
• Cancer (CBM-F1) 
• Vascular diseases (CBM-H1)




Development of New Diagnostic System​​​​​​​

Our discovery of Kca2.3 and ​​​​​​​Kca ​​​​​​​ 3.1 channels that perform key roles for functions of ​​​​​​​blood vessel provides fundamental principles for the development of ​​​​​​​new ​​​​​​​diagnostic ​​​​​​​system. ​​​​​​​


We discovered that abnormal expression of the potassium channels gives rise to ​​​​​​​endothelial cell fibrosis, ​​​​​​​proliferative diseases, ​​​​​​​arteriosclerosis, ​​​​​​​ gestational ​​​​​​​hypertension, ​​​​​​​ etc. ​​​​​​​


However, ​​​​​​​current ​​​​​​​diagnostic method is not able to perceive deterioration of the blood ​​​​​​​vessel until it becomes severely damaged by blood clogging or serious external ​​​​​​​symptoms. ​​​​​​​


In order to prevent deterioration of blood vessel health, it is important to diagnose ​​​​​​​healthy ​​​​​​​​​​​​state ​​​​​​​of ​​​​​​​blood ​​​​​​​vessel regularly by direct measurement. Unfortunately, ​​​​​​​ ​​​​​​​current ​​​​​​​diagnostic ​​​​​​​method is to examine the level of triglyceride and LDL in the blood, ​​​​​​​which ​​​​​​is an indirect ​​​​​​​measurement and only predicts probability of healthy ​​​​​​​ state of blood vessels.


Upon our discovery, abnormal regulation of the potassium channels ​​​​​​​provides corresponding factors of regulation. We found that the level of regulation factors are ​​​​​​​closely ​​​​​​​related with the ​​​​​​​ level of expression of ​​​​​​​the K+ channels. Our principal of new ​​​​​​​diagnostic ​​​​​​​system is to ​​​​​​​measure the level of regulation factors of ​​​​​​​Kca2.3 and ​​​​​​​Kca ​​​​​​​ 3.1 ​​​​​​​channels so that ​​​​​​​the healthy ​​​​​​​state of blood vessels are able to be ​​​​​​​diagnosed real-time ​​​​​​​manner. ​​​​​​​




Cellion Biomed opens the Bio USA exhibition in Boston, USA from June 4th to 8th, 2023.


We plan to introduce anti-fibrotic and autoimmune disease treatments. In particular, hypertrophic scar treatment and the technology of the world's first vascular disease diagnosis kit will be introduced.

"포타슘 채널 이온 조절로 특발성 폐섬유증 타깃"
김성진 셀라이온바이오메드 대표 "브릿지바이오와 협업해 내년 美 임상 진입 목표


더벨, 2022.09.23

bottom of page